Are you selecting any specific patient cohort with metastatic NSCLC for treatment with the CheckMate 9LA protocol of ipilimumab + nivolumab + 2 cycles of chemotherapy?

I am not currently using this regimen although, it is certainly an acceptable regimen.

When looking at potential subgroups that might benefit from the CheckMate 9LA regimen, I consider patients with squamous cell carcinoma, where the HR was 0.63; PD-L1 less than 1%, which demonstrated similar 2y OS to those with PD-L1> 1%. Another intriguing group is patients with brain metastases whe...

It is important that we acknowledge that we have no head to head trials comparing immune checkpoint inhibitors (ICI) + /Chemo vs ICI alone or combined ICI, so we are doing our best to extrapolate patient subsets that seem to have done best with specific treatment compared to an outdated standard of ...

The data from the recent 2-year update of 9LA published in ESMO Open was relatively encouraging for patients with squamous NSCLC in particular, 2 year PFS was 17% for 9LA versus 7% for chemo alone. Similarly, for PD-L1 negative tumors, 2 yr PFS was 20% with 9LA vs. 5% with chemo alone. As such I wou...

I try to stay away from quadruplet therapies Nivo+Ipi+chemox2 (9LA) or atezo+bev+chemo (IMpower150) given increased AE's and irAE's. In a borderline performance status patient who may or may not tolerate full chemotherapy, I start with KEYNOTE-189 intent but if they cannot tolerate triplet, I discon...